Picture BIO Deutschland Corona Special Germany 2020 650x80px
Person › Details

Peter Vogt (Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY))

Vogt, Peter (Epigenomics 201601 Investor + Public Relations)


Organisation Organisation Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY)
  Group Epigenomics (Group)
Products Product public relations / investor relations / marcom (services)
  Product 2 Epi proColon® blood test

Epigenomics AG. (1/8/16). "Press Release: Epigenomics Receives FDA Notification about Status of Pending Approval Decision for Epi proColon". Berlin.

Epigenomics AG, Berlin, Germany, (Frankfurt Prime Standard: ECX; ISIN: DE000A11QW50) the German-American cancer molecular diagnostics company, today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that the already submitted and available data for Epigenomics’ blood-based colorectal cancer (CRC) screening test Epi proColon® would allow the agency to come to a final determination on its safety and effectiveness. Given that no new data would be required before reaching a final decision on the premarket approval (“PMA”) submission, FDA would expect that final stages of the review process would be completed in the near future.

According to the FDA, final approval of the Company’s application is subject to the resolution of minor outstanding topics, such as the use of appropriate language in the product labeling.

Epigenomics will work closely with the FDA to reach the final approval decision within the next few months.

Upon approval, Epi proColon® would be the first and only FDA-approved blood-based test for the detection of colorectal cancer. Epi proColon® will be made available in the United States jointly with the Company’s strategic commercialization partner Polymedco.

– End of Ad hoc –

Contact Epigenomics AG

Peter Vogt, Investor & Public Relations
Epigenomics AG
Geneststraße 5
10829 Berlin
Phone +49 (0) 30 24345 386

Epigenomics legal disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

The information contained in this communication does not constitute nor imply an offer to sell or transfer any product, and no product based on this technology is currently available for sale by Epigenomics in the United States or Canada. The analytical and clinical performance characteristics of any Epigenomics product based on this technology which may be sold at some future time in the U.S. have not been established.

Record changed: 2019-06-09


Picture Fairtec GmbH We Optimise the ROI of Your Event 650x65px

More documents for Peter Vogt

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at (European life sciences) and (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture [iito] Made Without Love 650x80px

» top